FGF21 and metabolic dysfunction-associated steatotic liver disease: Elevated levels of various circulating biomarkers have been described in patients with NAFLD, including AST and ALT, cytokeratin 18 (CK-18) fragments, apolipoprotein A1, total bilirubin, hyaluronic acid, C-reactive protein, fibroblast growth factor-21, interleukin 1 receptor antagonist, adiponectin, and TNF-α [83].